Nexalin Uncovers New Cognitive Gains in Alzheimer’s Trial Data…

Event summary

Nexalin’s secondary analysis of ADAS-Cog data from a 46-patient trial revealed previously unreported improvements in memory, comprehension, and language function in Alzheimer’s patients.
Half of evaluable active-arm participants achieved a clinically meaningful improvement of four or more points on the ADAS-Cog, with the largest gains observed in patients with the greatest cognitive impairment at baseline.
Findings will guide endpoint selection and patient-selection strategy for Nexalin’s planned U.S. Alzheimer’s pilot study, following a completed Q-Submission meeting with the FDA.

The big picture

Nexalin’s deeper dive into cognitive subscales highlights the potential of its non-invasive neurostimulation technology to target specific cognitive domains in Alzheimer’s patients. The findings come as the biotech sector increasingly focuses on precision medicine approaches for neurodegenerative diseases. The strategic anomaly here is the post-hoc nature of the analysis, which, while hypothesis-generating, lacks the rigor of prespecified endpoints. The company’s ability to translate these insights into a successful pilot study will be critical for its long-term positioning in the Alzheimer’s treatment landscape.

What we're watching

Clinical Validation: Whether the exploratory findings can be replicated in a larger, controlled study and gain FDA acceptance as endpoints.
Regulatory Pathway: The pace at which Nexalin advances its U.S. Alzheimer’s pilot study, incorporating FDA feedback from the Q-Submission meeting.
Patient Selection: How Nexalin’s refined patient-selection strategy based on baseline cognitive impairment impacts trial outcomes.